Unblinded, Multicenter, Prospective Follow-up of Long-Term Consequences of Initiating Patients With Parkinson's Disease on Either Pramipexole or Levodopa.

Trial Profile

Unblinded, Multicenter, Prospective Follow-up of Long-Term Consequences of Initiating Patients With Parkinson's Disease on Either Pramipexole or Levodopa.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2016

At a glance

  • Drugs Pramipexole (Primary) ; Levodopa/carbidopa
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms CALM-PD
  • Most Recent Events

    • 13 Dec 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top